Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment

被引:1
作者
Alhajj, Sleiman [1 ]
Gencer, Salih [1 ]
机构
[1] Istanbul Medipol Univ, Sch Med, Istanbul, Turkey
来源
2020 IEEE/ACM INTERNATIONAL CONFERENCE ON ADVANCES IN SOCIAL NETWORKS ANALYSIS AND MINING (ASONAM) | 2020年
关键词
COVID-19; Drug-Drug interaction; side effects; infectious disease; CHLOROQUINE; ATAZANAVIR; EFFICACY;
D O I
10.1109/ASONAM49781.2020.9381474
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Following the rapid spread and evolution of the novel Corona virus starting in December 2019, the lack of a vaccine or a medication that proved to be effective for Covid-19 was addressed as a major concern by the World Health Organization (WHO), the Center for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA) [1]. Accordingly, physicians from countries like China and Korea rushed to provide some potential treatment for Covid-19 from their experience in treating patients of the novel Coronavirus - they used antiviral medications like lopinavir, ritonavir, chloroquine, hydroxychloroquine, ribavirin, interferon, remdesivir, sofosbuvir, nitazoxanide, favipiravir, ivermectin, etc. [1]-[3]. These drugs showed improvement in conditions of Covid-19 patients when used individually, or sometimes using a combination of multiple of them. This does not mean that any combinations of these drugs could be beneficial. Some combinations can be lethal and may lead to increasing health risks or mortality. The drugs are being used in vitro (i.e., on cells in a laboratory for experiments) and vivo (i.e., on humans or animals as clinical trials). In vitro analysis, the chemical structure of the drug and the disease are analyzed to generate a hypothesis on the performance of the drug, then the hypothesis is tested in vivo to measure the actual performance of the drug on a living creature. Although these drugs showed promising results with proper dosage, overdose and incorrect combination with other drugs sometimes proved to be lethal. The effectiveness and side-effects of some of these drugs as reported by recent researchers and trials are described in this paper. We address some related research questions concerning the side effects of the covered drugs and their interaction with other drugs based on some well tested results extracted from approved websites of drug-drug interactions. The findings are interesting and confirmed favipiravir as the most effective and safe compared to the others, and this coincides with and supports the announcement by Turkish Ministry of Health where favipiravir has been used in treating COVID-19 patients since the early days.
引用
收藏
页码:803 / 810
页数:8
相关论文
共 32 条
  • [1] Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
  • [2] A systematic review on the ef ficacy and safety of chloroquine for the treatment of COVID-19
    Cortegiani, Andrea
    Ingoglia, Giulia
    Ippolito, Mariachiara
    Giarratano, Antonino
    Einav, Sharon
    [J]. JOURNAL OF CRITICAL CARE, 2020, 57 : 279 - 283
  • [3] Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
    Deng, Lisi
    Li, Chunna
    Zeng, Qi
    Liu, Xi
    Li, Xinghua
    Zhang, Haitang
    Hong, Zhongsi
    Xia, Jinyu
    [J]. JOURNAL OF INFECTION, 2020, 81 (01) : E1 - E5
  • [4] New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    Devaux, Christian A.
    Rolain, Jean-Marc
    Colson, Philippe
    Raoult, Didier
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
  • [5] Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI [10.1128/CMR.00028-20, 10.1038/s41432-020-0088-4]
  • [6] Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
    Elfiky, Abdo A.
    [J]. LIFE SCIENCES, 2020, 248
  • [7] Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-Social Distancing Measures
    Fong, Min W.
    Gao, Huizhi
    Wong, Jessica Y.
    Xiao, Jingyi
    Shiu, Eunice Y. C.
    Ryu, Sukhyun
    Cowling, Benjamin J.
    [J]. EMERGING INFECTIOUS DISEASES, 2020, 26 (05) : 976 - 984
  • [8] Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
    Gao, Jianjun
    Tian, Zhenxue
    Yang, Xu
    [J]. BIOSCIENCE TRENDS, 2020, 14 (01) : 72 - 73
  • [9] Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
    Geleris, Joshua
    Sun, Yifei
    Platt, Jonathan
    Zucker, Jason
    Baldwin, Matthew
    Hripcsak, George
    Labella, Angelena
    Manson, Daniel K.
    Kubin, Christine
    Barr, R. Graham
    Sobieszczyk, Magdalena E.
    Schluger, Neil W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) : 2411 - 2418
  • [10] The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer
    Gunn, G. Brandon
    Debnam, J. Matthew
    Fuller, Clifton D.
    Morrison, William H.
    Frank, Steven J.
    Beadle, Beth M.
    Sturgis, Erich M.
    Glisson, Bonnie S.
    Phan, Jack
    Rosenthal, David I.
    Garden, Adam S.
    [J]. CANCER, 2013, 119 (17) : 3162 - 3169